tirzepatide latest news https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound Tirzepatide is NO longer in

In the WEGOVY clinical trials for weight reduction and long-term maintenance, 233 (9%) WEGOVY-treated patients were aged 65 to 75 years and 23 (1%) WEGOVY-treated patients were aged 75 years and older [see Clinical Studies (14.2)]

Monitoring Report: GLP-1 RA Prescribing Trends December 2025 Data | medRxiv

Ensuring proper sleep through effective management and treatment can significantly improve patient health and quality of life

Gastrointestinal effects Every GLP-1 based medication shares a core set of gastrointestinal side effects because they stem from the mechanism of action itself, slowing gastric emptying and altering gut motility

Individuals taking Wegovy may experience side effects that could interact with the donation process, particularly if they have recently experienced gastrointestinal symptoms leading to reduced fluid or nutritional intake